A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants

J

Janssen (J&J Innovative Medicine)

Status and phase

Completed
Phase 1

Conditions

Healthy

Treatments

Drug: JNJ-63623872 2400 milligram (mg)
Drug: JNJ-63623872 3000 mg
Drug: Placebo (Matching with JNJ-63623872 2400 mg)
Drug: JNJ-63623872
Drug: Placebo (Matching with Moxifloxacin)
Drug: Moxifloxacin
Drug: Placebo (Matching with JNJ-63623872 Dose)
Drug: Placebo (Matching with JNJ-63623872 3000 mg)

Study type

Interventional

Funder types

Industry

Identifiers

NCT02658825
63623872FLZ1005 (Other Identifier)
2015-004365-82 (EudraCT Number)
CR108108

Details and patient eligibility

About

The purpose of this study is to evaluate the effect of JNJ-63623872 on the QT/QTc interval at supratherapeutic exposure in healthy participants (Panel 2).

Full description

This is a two-part Phase 1 study consisting of a dose escalation part (Panel 1) and a thorough QT (TQT) part (Panel 2). Panel 1 will be a double-blind (neither the researchers nor the participants know what treatment the participant is receiving), randomized (study medication assigned to participants by chance), placebo-controlled dose escalation study in healthy participants to determine the safety, tolerability and pharmacokinetics of JNJ-63623872 after administration of single doses of 2400 milligrams (mg) and 3000 mg under fasted conditions. The final dose to be used in the Panel 2 will be determined based on the results of this dose escalation part. An interim analysis will be conducted on Panel 1 to select the dose for Panel 2. Panel 2 will be a double-blind, double-dummy, randomized, 3-period crossover (the same medications provided to all participants but in different sequence), placebo- and positive controlled study to evaluate the effect of JNJ-63623872 on the QT/QTc interval in healthy participants. Participants' safety will be monitored throughout the study.

Enrollment

66 patients

Sex

All

Ages

18 to 50 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Each participant must sign an Informed consent form (ICF) indicating that he or she understands the purpose of and procedures required for the study and is willing to participate in the study
  • Participant must be willing and able to adhere to the prohibitions and restrictions specified in the protocol
  • A female participant must agree not to donate eggs (ova, oocytes) during the study and for at least 90 days after receiving the (last dose of) study drug
  • A male participant who is sexually active with a woman of childbearing potential must agree to use two effective methods of contraception during the study and for at least 90 days after receiving the (last dose of) study drug, and a male participant must also not donate sperm during the study and for at least 90 days after receiving the (last dose of) study drug
  • Participants must be non-smokers for at least 3 months prior to Screening
  • Participants must have a Body Mass Index (BMI) between 18.0 and 30.0 kilogram per meter^2 (kg/m^2) (inclusive) at Screening

Exclusion criteria

  • Participant has a history of current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the Investigator considers should exclude the participant or that could interfere with the interpretation of the study results
  • Participants with a history of clinically relevant heart rhythm disturbances including atrial, junctional, re-entry, and ventricular tachycardias, and heart blocks
  • Participants with unusual T wave morphology (such as bifid T wave) likely to interfere with QTc measurements
  • Participants with electrolyte abnormalities (hypokalemia, hypocalcemia, hypomagnesemia) of grade 2 or above within 21 days prior to the (first) intake of the study drug
  • Participants with a breast implant or a history of thoracic surgery likely to cause abnormality of the electrical conduction through thoracic tissues
  • Participant has taken any disallowed therapies (Concomitant Therapy) before the planned (first) intake of study drug
  • Participant has known allergies, hypersensitivity, or intolerance to JNJ-63623872, moxifloxacin or its excipients

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

66 participants in 8 patient groups

Panel 1: Dose level 1
Experimental group
Description:
Participants will receive either treatment A (JNJ-63623872, 2400 milligram (mg) tablet orally once on Day 1) or treatment B [(placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1].
Treatment:
Drug: Placebo (Matching with JNJ-63623872 2400 mg)
Drug: JNJ-63623872 2400 milligram (mg)
Panel 1: Dose level 2
Experimental group
Description:
Participants will receive either treatment C (JNJ-63623872, 3000 mg tablet orally once on Day 1) or treatment D [placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1].
Treatment:
Drug: Placebo (Matching with JNJ-63623872 3000 mg)
Drug: JNJ-63623872 3000 mg
Panel 2: Treatment EFG
Experimental group
Description:
Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
Treatment:
Drug: Placebo (Matching with JNJ-63623872 Dose)
Drug: Placebo (Matching with Moxifloxacin)
Drug: Moxifloxacin
Drug: JNJ-63623872
Panel 2: Treatment FGE
Experimental group
Description:
Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
Treatment:
Drug: Placebo (Matching with JNJ-63623872 Dose)
Drug: Placebo (Matching with Moxifloxacin)
Drug: Moxifloxacin
Drug: JNJ-63623872
Panel 2: Treatment GEF
Experimental group
Description:
Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
Treatment:
Drug: Placebo (Matching with JNJ-63623872 Dose)
Drug: Placebo (Matching with Moxifloxacin)
Drug: Moxifloxacin
Drug: JNJ-63623872
Panel 2: Treatment GFE
Experimental group
Description:
Participants will receive treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 1; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 2; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
Treatment:
Drug: Placebo (Matching with JNJ-63623872 Dose)
Drug: Placebo (Matching with Moxifloxacin)
Drug: Moxifloxacin
Drug: JNJ-63623872
Panel 2: Treatment FEG
Experimental group
Description:
Participants will receive treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 1; followed by treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 2; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 3. A washout period of 5 days will be maintained between each treatment period.
Treatment:
Drug: Placebo (Matching with JNJ-63623872 Dose)
Drug: Placebo (Matching with Moxifloxacin)
Drug: Moxifloxacin
Drug: JNJ-63623872
Panel 2: Treatment EGF
Experimental group
Description:
Participants will receive treatment E (JNJ-63623872 dose selected in Panel 1 tablet and placebo matching with moxifloxacin) in Period 1; followed by treatment G (placebo matching with JNJ-63623872 and placebo matching with moxifloxacin) in Period 2; followed by treatment F (placebo matching with JNJ-63623872 and moxifloxacin 400 mg capsule) in Period 3. A washout period of 5 days will be maintained between each treatment period.
Treatment:
Drug: Placebo (Matching with JNJ-63623872 Dose)
Drug: Placebo (Matching with Moxifloxacin)
Drug: Moxifloxacin
Drug: JNJ-63623872

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems